Laxmi Dental · forward-looking guidance across the available source record.
Guidance tracker
Management stated internal aspiration to return to 17.5% EBITDA (FY25 level) and move toward 20% range, contingent on normalized tariff environment (no surprises), ESOP costs halving from second year onwards, and scanner mix stabilization.
CEO confirmed already delivering ~25% growth in international markets; expects this 20-25% range to be achievable in FY27 provided no additional tariff disruptions emerge from the US.
Management expects robust YoY performance in both domestic lab and aligner businesses in Q4, citing positive January 2026 trends and new strategic initiatives implemented in Q3.
Target to increase company-level digital penetration from 79% to 90%, described as the 'pivoting point' for potential 100% digital lab transition, with both scanner sales and 'scan as a service' models being deployed.